echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The growth of specialty drugs has become a big market

    The growth of specialty drugs has become a big market

    • Last Update: 2017-02-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [editor's point of view of chinapharma.com] improve the quality and promote the transformation of China from a big pharmaceutical country to a powerful pharmaceutical country In recent years, China's pharmaceutical policy has been continuous In 2016, under the implementation of the two vote system, document 94 and the policy of replacing business tax with value-added tax, many pharmaceutical enterprises' performance has been turbulent But according to the statistics of relevant data, in the past few years, specialty drugs have become more and more big market sales, with the potential no less than that of anti-cancer drugs From the medical data of the United States, the growth rate of specialty drugs in 2015 is 22.6%, and the annual expenditure per person (pmpy) is $311.11 Although the growth trend of specialty drugs market will slow down to a more sustainable level in the future, it is expected to grow at a relatively stable growth rate of 2 digits, which can reach 22.3% and 21.3% in 2016 and 2017 respectively Compared with the per capita drug use level of China and other developed countries, the pharmaceutical market in China has not been really opened up so far, the drug demand and health demand of the people have not been really met, the demand for drug use in the subdivision field of the medical market is more, and the market potential is huge With the increase of the proportion of specialized drugs, the disease spectrum is more detailed, the rigid demand of the medical market is gradually opening, and more and more new demands appear, including oncology, cardio cerebrovascular, blood and health care These fields have given birth to Hengrui pharmaceutical, Yibai pharmaceutical, Tianshili, Zhongheng group, Yiling pharmaceutical, xinlitai, dong'a-jiao, Yunnan Baiyao, Tangshan Beijian and other companies It is reported that under the policy background of limited use of traditional Chinese medicine injection, Lizhu Group actively promotes the safety re evaluation and pharmacoeconomics research of Shenqifuzheng injection In 2015, the sales volume of Shenqifuzheng exceeded 1.5 billion yuan, and in the first quarter of 2016, Shenqifuzheng achieved a steady growth of about 10%, and it is expected to achieve a steady growth of 5% - 10% throughout the year In the evening of January 26, Laimei pharmaceutical announced that the annual profit in 2016 is expected to be 60 million yuan – 65 million yuan, an increase of 191.09% - 215.34% over the same period of last year The company said that during the reporting period, the product structure of the company was further optimized, the sales market of special products and other products was further expanded, and the overall gross profit rate was increased China's specialty drugs, such as laimeishu, kanalin, and Utilins, continue to increase the volume of new targets The company's heavyweight products, such as esomeprazole, nano carbon suspension, and neumeishun, are domestic or international products At present, the sales of the above products are in good condition The sales of the heavyweight varieties of laimeishu have a compound growth rate of 242% in 2016-2018 In addition, UL will gradually transform into an adult specialist drug developer UL announced on January 6 that the group's application for insulin glargine bulk drug and insulin glargine injection has been approved, and the product is expected to be put into production formally in April For Chinese pharmaceutical enterprises, before the core competitiveness is really formed, scale and diversification can provide enterprises with more R & D funds, survival probability and market opportunities, and can obtain the real value core Nowadays, various industrial policies are becoming increasingly clear, and the development of pharmaceutical industry is at the turning point of the transformation period At this time, diversified professional development is a good opportunity The increasing utilization rate of specialty drugs may indicate that the existing drug team is expanding and the prescription of specialty drugs is frequently prescribed The main factors driving the increase of pmpy's expenditure on specialty drugs every year are the increase of specialty drug brands and the acceleration of the development of expensive and targeted specialty drugs Among them, Dongrui pharmaceutical has become a more "moistening" group in this field due to its specialty drug brand.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.